

# UCSF

## UC San Francisco Previously Published Works

### Title

Diabetes Specialists Value Continuous Glucose Monitoring Despite Challenges in Prescribing and Data Review Process.

### Permalink

<https://escholarship.org/uc/item/4x96b0sh>

### Journal

Journal of Diabetes Science and Technology, 17(5)

### Authors

Kompala, Tejaswi  
Neinstein, Aaron  
Wong, Jenise

### Publication Date

2023-09-01

### DOI

10.1177/19322968221088267

Peer reviewed

# Diabetes Specialists Value Continuous Glucose Monitoring Despite Challenges in Prescribing and Data Review Process

Journal of Diabetes Science and Technology  
2023, Vol. 17(5) 1265–1273  
© 2022 Diabetes Technology Society



Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/19322968221088267  
journals.sagepub.com/home/dst



Tejaswi Kompala, MD<sup>1</sup> , Jenise Wong, MD, PhD<sup>2</sup> ,  
and Aaron Neinstein, MD<sup>1,3</sup> 

## Abstract

**Background:** Diabetes clinicians are key facilitators of continuous glucose monitoring (CGM) provision, but data on provider behavior related to CGM use and CGM generated data are limited.

**Methods:** We conducted a national survey of providers caring for people with diabetes on CGM-related opinions, facilitators and barriers to prescription, and data review practices.

**Results:** Of 182 survey respondents, 73.2% worked at academic centers, 70.6% were endocrinologists, and 70.7% practiced in urban settings. Nearly 70% of providers reported CGM use in the majority of their patients with type 1 diabetes. Half of the providers reported CGM use in 10% to 50% of their patients with type 2 diabetes. All respondents believed CGM improved quality of life and could optimize diabetes control. We found no differences in reported rates of CGM use based on providers' years of experience, patient volume, practice setting, or clinic type. Most providers reviewed CGM data each visit (97.7%) and actively involved patients in the data interpretation (98.8%). Only 14.1% of clinicians reported reviewing CGM data without any prompting from patients or their family members outside of visits. Most providers (80.7%) reported their CGM data review was valued by patients although only half reported having adequate time (45.1%) or an efficient process (56.1%) to do so.

**Conclusions:** Despite uniform support for CGM by providers, ongoing challenges related to cost, insurance coverage, and difficulties with prescription were major barriers to CGM use. Increased use of CGM in appropriate populations will necessitate improvements in data access and integration, clearly defined workflows, and decreased administrative burden to obtain CGM.

## Keywords

continuous glucose monitoring, diabetes mellitus, digital health, endocrinologists, telehealth

## Introduction

The accuracy and usability of continuous glucose monitoring (CGM) technology has dramatically improved in the past decade, leading to enhanced quality of life and improved glycemic control.<sup>1–5</sup> However, despite guidelines and emerging evidence supporting CGM use for all people with type 1 diabetes (T1D) and many people with type 2 diabetes (T2D),<sup>6,7</sup> uptake remains low.<sup>8</sup>

Although diabetes clinicians are key facilitators of CGM use, there has been limited investigation into their role in the extent to which their patients use CGM. In addition to being the prescribers of CGM, diabetes clinicians play an important role in promoting adherence to CGM and providing education and support.<sup>9</sup> A prior study examined clinician perspectives on barriers and facilitators of device use and found that younger, academic, urban clinicians treated more

patients using CGM and were more likely to have positive attitudes toward technology.<sup>9</sup> Another study of rural providers identified that lack of provider experience and proficiency with diabetes devices was a major factor in limited CGM use in their patient population.<sup>10</sup> A recent investigation

<sup>1</sup>Division of Endocrinology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

<sup>2</sup>Division of Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA

<sup>3</sup>Center for Digital Health Innovation, University of California, San Francisco, San Francisco, CA, USA

## Corresponding Author:

Tejaswi Kompala, MD, Division of Endocrinology, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 500, San Francisco, CA 94143, USA.

Email: Tejaswi.Kompala@ucsf.edu

has demonstrated disparities in prescribing diabetes technology,<sup>11</sup> further spotlighting the critical role of the provider in CGM use.

While provider opinion has been previously considered with regard to patient CGM use, implementation and uptake of “new” technologies are influenced by myriad factors. The Consolidated Framework for Implementation Research (CFIR) is a widely used implementation science framework that recognizes five specific domains influencing technology adoption.<sup>12</sup> As applied to the diabetes clinician’s role in CGM uptake, the domains include characteristics of CGM itself, the outer setting (external influences, eg, patient preference, national guidelines, insurance coverage, reimbursement), the inner setting (internal influences, eg, clinic infrastructure), the individual (eg, the diabetes clinician), and the implementation process. We used CFIR to comprehensively evaluate the provider’s role in CGM adoption.

Although retrospective review of diabetes data by patients has been associated with improved glycemic control,<sup>13</sup> less is known about how providers use CGM-generated data in patient care. From the provider perspective, diabetes care has historically relied on interpretation of glycemic data to inform treatment recommendations.<sup>14</sup> However, with recent broadened use of CGM, specific provider behaviors related to CGM generated data review and interpretation are not well described. Key steps in the CGM data review process that require further exploration include methods of data access, frequency of data review inside and outside of scheduled encounters, electronic health record integration strategies, and billing and reimbursement practices.

As CGM technology improves and evidence grows supporting the use of CGM to achieve better clinical outcomes, more investigation is needed to understand facilitators and barriers to widespread use of CGM in real-world clinical practice. The primary aims of this study were to (1) examine relationships between provider attributes and rates of CGM use among their patients, (2) characterize provider behavior related to CGM data, and (3) describe the implementation landscape of CGM, including facilitators and barriers to broader use.

## Methods

### Study Population and Recruitment

We administered a national cross-sectional survey to clinicians who treat people with diabetes, between March 12, 2020, and April 30, 2020. The intended survey population included primary care doctors, endocrinologists, advanced care practitioners, diabetes educators, pharmacists, and endocrinology fellows caring for pediatric and/or adult patients with diabetes using CGM.

The anonymous survey was delivered electronically using Qualtrics, a secure web-based application widely used for data capture in research studies.<sup>15</sup> The survey was disseminated using a broad recruitment strategy of email and social

media directed toward diabetes-focused clinicians, including listservs through the T1D Exchange Clinic Network, ADA Diabetes Technology Interest Group, Association of Program Directors in Endocrinology, Diabetes and Metabolism, and social media groups for diabetes providers. Recruitment emails linked directly to the online Qualtrics survey. There were no financial incentives related to completion of the survey. The University of California, San Francisco Institutional Review Board approved the research protocol.

### Measures

We developed a 55-question survey evaluating provider characteristics, patient demographics, and estimated patient use of CGM. We additionally evaluated providers’ perspectives on CGM, facilitators and barriers to CGM prescription, data review practices, description of clinical infrastructure for CGM, and reimbursement practices. Two open-ended free response questions queried participants’ opinions on CGM-related benefits and challenges. Survey questions were adapted from key references<sup>9,10</sup> and the National Institutes of Health (NIH) proficiency scale.<sup>16</sup> We conducted iterative pilot testing with key stakeholders, including endocrinologists, diabetes educators, and a diabetes patient advocate, to adapt and finalize survey language.

### Analysis

Descriptive statistics were used to report provider and practice demographic information, and prevalence of Likert scale answers to questions evaluating practice patterns or CGM-related opinions. Chi-square testing was used for the comparative aims to explore relationships between clinician, practice, and patient variables. Using thematic analysis, we mapped survey responses to open-ended questions onto the CFIR.<sup>17</sup> Content was categorized according to CFIR domain, and emerging themes with highest frequency were analyzed.<sup>17,18</sup> Data were collected directly via Qualtrics. Quantitative data analyses were conducted using Stata version 16 (StataCorp, College Station, TX). For all statistical tests, significance was set to  $\alpha = .05$ .

## Results

In total, 195 providers completed the survey. After excluding those who did not take care of patients with diabetes ( $n = 3$ ) or did not take care of patients using CGM ( $n = 10$ ), 182 responses were used in the subsequent analysis.

Participating clinicians were predominantly female (73.2%) and endocrinologists (70.6%) with varying years of experience (Table 1). Practice setting varied although most providers practiced in academic health systems (77.4%) and urban settings (70.7%). The majority of respondents (69.4%) reported CGM use in >51% of their T1D patients. Reported CGM use in type 2 diabetes patients was lower, with half of

**Table 1.** Clinician and Practice Characteristics (n = 182<sup>a</sup>).

Clinician demographics	%
Female gender	73
White/Caucasian	68
Asian/Asian American	22
Hispanic/Latinx	5.9
Black or African American	1.2
Other or multiple races	3.0
Professional status	
Endocrinologist	71
Advanced care practitioner (NP/PA)	10
CDCES (RN/RD)	12
Years post-training	
Still in training	11
<10 years	35
11-20 years	30
>20 years	24
Practice setting—clinic type	
Academic Medical Center/University	77
Hospital Affiliated	
Veterans Affairs Medical Facilities	2.3
Community Hospital Affiliated	5.7
Large group practice	5.7
Small group practice	5.1
Solo practice	1.1
Digital/Virtual clinic	0.6
Other	1.7
Practice setting—location	
Urban	71
Suburban	25
Rural	4.6
Percent of patients with public insurance	
<10%	4.1
10%-25%	11
26%-50%	39
51%-75%	25
>75%	12
Not sure	8.8
Patient age groups	
See pediatric patients	37
Exclusively see pediatric patients	10


Abbreviation: CDCES, Certified Diabetes care and education specialist; NP, Nurse Practitioner; PA, Physician Assistant; RN, Registered Nurse; RD, Registered Dietitian.

<sup>a</sup>Data were missing for the following: gender n = 14; ethnicity n = 13, professional status n = 12, years post training n = 14, clinic type n = 5, practice location n = 8, public insurance n = 12, patient age n = 12.

the respondents noting less than 10% usage and another half reporting between 10% and 50% usage (Figure 1).

### CGM Data Review Frequency and Efficiency

Regarding CGM data review frequency, nearly all providers reviewed CGM data during each scheduled visit (97.7%) and actively involved patients in the data review and interpretation



**Figure 1.** Percent of patients who use CGM as reported by survey respondents. Abbreviation: CGM, continuous glucose monitoring.

(98.8%). If contacted by patients or patients’ family members outside of the visits, 71.7% reported reviewing CGM data “often” or “always.” However, only 14.1% of clinicians reported reviewing CGM data outside of a scheduled visit without any prompting from the patient or family, consistent with a definition of remote patient monitoring.<sup>19</sup>

We asked about the process to obtain and view CGM data during a typical scheduled in-clinic visit and found that 56.1% of clinicians agreed they had an efficient process. About two-thirds (68.9%) of respondents endorsed having adequate software and computer resources to visualize the CGM data, but fewer (45.1%) endorsed adequate time to obtain and interpret the CGM data. Participants were asked how they accessed CGM data; multiple responses were permitted. Of all responses, the two most common methods for accessing CGM data during a scheduled visit were physically downloading data from a device (84.7%) or accessing data online from a continuously connected device (62.9%) (Table 2). Despite limitations in the efficiency of the review process, nearly all (98.7%) agreed it was worth the effort to have CGM data to discuss with the patient.

### Electronic Health Record Practices

Respondents equally agreed (40.9%) and disagreed (41.5%) about having an efficient process to include CGM data in the electronic health record (EHR). Clinicians reported manual entry of CGM data into the visit note (35.0%) or attachment into EHR as a scanned document or image (47.5%). A minority of respondents (15.4%) reported CGM data being directly integrated into the EHR. Of those who reported direct EHR integration, there were no significant differences in their provider characteristics; the majority (74.1%) practiced at academic health centers.

### Reimbursement Practices

Regarding reimbursement, 78.8% of providers reported billing for CGM data interpretation during a visit, while a much lower number (40.1%) sought reimbursement for CGM interpretation

**Table 2.** Methods of CGM Data Access.

	% who responded “often” or “always”
Clinic staff download data during visit, n=164	85
Patient’s device is continuously connected, n = 162	63
Intermittent electronic sharing by patient, n = 158	25
Patient brings report (paper or electronic) to visit, n = 158	11
Data viewed directly on device screen, n = 157	8.9

Abbreviation: CGM, continuous glucose monitoring.

**Table 3.** Provider Opinions on CGM, n = 166<sup>a</sup>.

	% who “agree” or “strongly agree”
CGM can increase quality of life	100
CGM optimizes diabetes control	100
CGM helps provide more data	99
My patients are interested in CGM	98
CGM and associated supplies are too costly	73
Sufficient resources for CGM training	60
Enough time to work with patients using CGM	55
My patients lack health literacy	7.3
Difficulty of obtaining CGM not worth the benefit	1.2
Insulin pump more valuable than CGM	1.2

Abbreviation: CGM, continuous glucose monitoring.

<sup>a</sup>Data were missing for the following: Sufficient resources, n = 2; Health literacy n = 1, Insulin Pump n = 1; Difficulty of obtaining CGM n = 1.

outside of a scheduled visit. We excluded providers in integrated health systems in which no fee for service billing is possible.

### Provider Opinion

We surveyed providers about CGM technology itself, provider perception, patient perception, and clinical infrastructure (Table 3). Nearly uniformly, clinicians agreed that CGM is an important diabetes technology that can increase quality of life, optimize diabetes control, and provide more data. The majority of respondents reported that their patients are interested in CGM. Despite strong patient and provider interest in CGM, respondents also endorsed prohibitive cost of CGM and associated supplies, and inadequate time and training resources (eg, clinical staff time, educational materials) to support patients’ CGM use.

### Practice Volume

Regarding practice volume, we compared providers who saw 50 or fewer patients with T1D per month (“low-volume” providers, n = 124) with providers who saw 51 or more patients with T1D per month (“high-volume” providers, n = 40). Low-volume providers and high-volume providers both reported CGM use in the majority of their patients with T1D (69.5% vs 69.1%,  $P = .95$ ). Low-volume providers and

high-volume providers had no significant differences in terms of years of practice, proportion of patients with public insurance, remote monitoring practices, or reimbursement practices. High-volume providers, as compared to low-volume providers, were more likely to report efficient data review processes (75.0% vs 50.0%,  $P = .01$ ). Regarding self-described proficiency with CGM, we used the NIH scale to categorize providers as “Novice,” “Intermediate,” “Advanced,” and “Expert.”<sup>16</sup> High-volume providers were more likely to describe themselves as “Expert” than low-volume providers (60.0% vs 33.1%,  $P = .02$ ).

### Provider Experience

Survey respondents had a wide range in years in practice (Table 1). Providers with 10 or fewer years of clinical practice were similar to those with 11 or greater years of practice: there were no significant differences in terms of reported CGM use, remote monitoring practices, reimbursement practices, perceived efficiency with CGM data review, or self-described proficiency with CGM.

### Provider Perspectives on CGM Use

Related to their roles as providers, respondents were asked two open-ended questions about benefits and challenges of

working with patients using CGM. Responses were categorized as facilitators or barriers according to the CFIR domains and themes that emerged most frequently are presented (Table 4). Top reported facilitators of CGM use were the providers' view of CGM as a beneficial tool for diabetes care and patients' desire to use CGM. Frequently reported barriers related to challenges in insurance coverage, burdensome prescription process, and prohibitive cost. Respondents also described the challenges in accessing CGM data and limited time and support for training patients and CGM review.

## Discussion

Recognizing their key role as facilitator for widespread CGM use, we studied providers involved in diabetes care and their role in CGM provision and data use. We used a comprehensive implementation framework to explore facilitators and barriers. To our knowledge, this study included the largest number of US endocrinologists to date on this topic and is the first to focus on factors such as EHR integration or reimbursement patterns.

Recent investigation has highlighted the role of endocrinologist as “gatekeeper” to people with diabetes accessing diabetes technology.<sup>20-22</sup> Previous studies evaluating the role of diabetes care provider have largely focused on primary care providers and diabetes educators.<sup>9,10,23</sup> Therefore, we felt it important to understand the role of the endocrinologist. Our collective findings contrast with prior published data which have focused primarily on diabetes educators in urban, academic settings.<sup>9</sup> First, we found no differences in positive beliefs toward CGM or reported rates of CGM use across provider experience level or practice setting. Second, the majority of clinicians in our survey endorsed strong patient interest in CGM. Broadly positive views on CGM, and higher reported rates of use compared to prior studies, may be explained by technology improvements and national trends toward increased CGM use. Finally, in contrast to prior study where only a minority of providers reported a need for more staff and time to support CGM use, this limitation was commonly endorsed in our study.<sup>9</sup> This may be related to a higher proportion of endocrinologists in our sample, for whom a large proportion of data review and documentation responsibilities fall.

Although regular CGM data review by providers is broadly encouraged, the nature of data review practices has not previously been characterized. Our evaluation identified that a majority of diabetes care providers review CGM data at every scheduled visit and actively involve patients in visit-based CGM data review, something patients and providers believed to be of value, despite the efficiency challenges. In diabetes care, a higher frequency of clinical interactions between the patient and care team is associated with improved control and increased treatment satisfaction.<sup>24,25</sup> However, despite most providers having continuous cloud-based access to CGM data, we found that most providers continued to

practice a traditional approach to chronic condition care with episodic visits every few months. A population health approach, leveraging unprompted, non-visit-based CGM review and asynchronous messaging, was rare. Although reimbursement structures for CGM interpretation exist, concerns about inadequate allowable billing frequency and lack of protected provider time for asynchronous review are likely to limit remote patient monitoring practices. In addition, providers who performed asynchronous CGM review were unlikely to seek reimbursement for their time or reported being unaware they were able to do so.

These data from a group largely comprised of diabetes specialists were collected at a unique moment in American health care, just as the COVID-19 pandemic was beginning to unfold at the start of 2020. The pandemic, and a shift toward telehealth, has since accelerated rapid restructuring of data access practices, including incorporation of fully web-based workflows.<sup>26-28</sup> Endocrinology practices, compared to other specialties, conducted visits largely through telemedicine throughout the pandemic.<sup>29</sup> By the start of 2021, Endocrinology was second only to Behavioral Health in continued telemedicine usage,<sup>30</sup> and many have described the data-driven coaching approach in diabetes care as particularly amenable to virtual care.<sup>31</sup> As we move into an ongoing hybrid of telemedicine and in person care,<sup>26,28,32</sup> these new data sharing processes will likely facilitate restructuring of traditional diabetes care models. Much more frequently, connected device data from smart pens, insulin pumps, and CGM are likely to be passively shared and continuously available, not just as a periodic data upload during a scheduled visit. Health systems with nontraditional care structures and newer digital coaching programs are able to more frequently review CGM data, as well as separately from synchronous one-on-one visits.<sup>33-35</sup> In addition, people with diabetes are increasingly open to remote monitoring, with the promise of receiving additional support from health care teams.<sup>36</sup> Although our survey found infrequent remote monitoring of CGM data, these data were collected at the onset of the COVID-19 pandemic, and we expect to see more frequent and consistent use of remote monitoring going forward. As the national health care landscape increasingly shifts toward value-based and risk-based reimbursement models, passively shared, connected device data may be key to proactive, population-based diabetes management.

Diabetes clinics largely lacked a sufficient and prepared remote data monitoring infrastructure for the pandemic. Knowing that our survey was distributed just as the pandemic was beginning across the United States, it was notable that the majority of clinicians depended on clinic staff to physically download device data in person. Only 56.1% of respondents felt that they had an efficient method for data access and only 45.1% had sufficient time for meaningful data review, despite the group being mostly diabetes specialists in academic centers. To facilitate appropriate clinical use of CGM data, and amid increasingly telehealth-driven care

**Table 4. Facilitators of and Barriers to CGM Provision and Data Use by Providers (CFR) (n = 87).**

CFR Domain	Themes	Representative quotes	
Intervention characteristics: CGM as a technology	Facilitators	<ul style="list-style-type: none"> <li>Comprehensive continuous data</li> <li>Real-time BG values facilitate behavior change</li> <li>Reduction of serious hypoglycemia</li> <li>Automatic upload</li> <li>Cost of CGM and associated supplies</li> <li>Technical issues and sensor failures; alarm fatigue</li> <li>Pain on insertion; adhesion and skin reactions</li> <li>Lack of interoperability among devices</li> <li>Large volume of data</li> </ul>	<ul style="list-style-type: none"> <li>"One of the tools that makes it easier for patients to do better with less interference in their lives. Alarms protect from lows and alert to act on highs"</li> <li>"[CGM] provides a wealth of data"</li> <li>"Ability to see real time data without upload required"</li> <li>"Cost, cost, always cost"</li> <li>"Many patients cannot afford to use them who would otherwise benefit"</li> <li>"Technical issues at times; sensor failures are very discouraging"</li> <li>"Sometimes too much data can make interpretation challenging"</li> </ul>
	Barriers	<ul style="list-style-type: none"> <li>Data-driven self-management decisions</li> <li>Patient empowerment and improved shared decision making</li> <li>Increase in patients' confidence and awareness</li> <li>Improved patient understanding of impact of dietary habits, activity, and medications</li> <li>Inadequate insurance coverage</li> <li>Challenging, time-consuming insurance approval process</li> <li>Strict eligibility criteria and burdensome documentation</li> <li>Delays in policy coverage of newer devices</li> <li>Inefficient interactions with DME companies</li> <li>Limitations to reimbursement for CGM data review</li> </ul>	<ul style="list-style-type: none"> <li>"Patients are very interested in using CGMs. We have patients coming in all the time now asking about them"</li> <li>"Patients can 'see' what happens, instead of me explaining what might happen"</li> <li>"Partnership: patients are expert in managing their diabetes"</li> <li>"Insurance coverage is our biggest challenge"</li> <li>"Limited coverage and too strict of qualifications"</li> <li>"Insurance authorization process is cumbersome and poorly defined"</li> <li>"[Insurance] is not covering these devices and thousands of patients are being discriminated against"</li> <li>"It shouldn't take 6 months to a year for insurances to add the newer, better option to their formulary"</li> </ul>
Outer setting: Patient needs, external policies	Facilitators	<ul style="list-style-type: none"> <li>No facilitators were reported</li> </ul>	<ul style="list-style-type: none"> <li>"The main challenges are getting patients to upload the data and not having easy ways of doing it ourselves"</li> <li>"Often takes more time than I have during a visit to review data and plan with patients"</li> <li>"Wearing [CGM] is not enough, need to have enough time and education to help patients best utilize the CGM data"</li> <li>"We have an archaic system in the clinic where [reports are printed] and scanned into charts—waste of time, paper, and often the reports don't make it into the EHR"</li> </ul>
	Barriers	<ul style="list-style-type: none"> <li>Inefficient process to download and access CGM data</li> <li>Time requirements for CGM data review and discussion</li> <li>Limited time and resources for patient training and education</li> <li>Difficult to integrate CGM data into EHR</li> </ul>	<ul style="list-style-type: none"> <li>"Being able to make educated therapeutic recommendations and empowering patients to make changes in their life [is valuable]."</li> <li>"I can make better decisions and improve patients' outcomes"</li> <li>"It makes decisions on changes to the insulin regimen substantially easier"</li> <li>"No formal provider and staff training on new devices—may be missing key new concepts"</li> <li>"I do not know how to troubleshoot site insertion, calibration"</li> </ul>
Individual: Provider knowledge and beliefs	Facilitators	<ul style="list-style-type: none"> <li>Improved clinical decision making</li> <li>Ability to safely personalize therapeutic recommendations</li> </ul>	<ul style="list-style-type: none"> <li>"CGM allows us to have a patient-centered exchange in reviewing the blood glucose and using shared decision making to determine next steps"</li> <li>"I have great support for getting prior authorizations for CGM but this process is still burdensome"</li> <li>"Developing a standardized process agreed upon by the entire practices"</li> <li>"EHR integration and reimbursement issues are solvable but our academic medical center gives little priority towards improved workflow"</li> </ul>
	Barriers	<ul style="list-style-type: none"> <li>Non-standardized training in CGM data interpretation or new device features</li> <li>Limited familiarity with CGM equipment and supplies required for new initiation</li> </ul>	<ul style="list-style-type: none"> <li>"CGM allows us to have a patient-centered exchange in reviewing the blood glucose and using shared decision making to determine next steps"</li> <li>"I have great support for getting prior authorizations for CGM but this process is still burdensome"</li> <li>"Developing a standardized process agreed upon by the entire practices"</li> <li>"EHR integration and reimbursement issues are solvable but our academic medical center gives little priority towards improved workflow"</li> </ul>
Implementation process: Planning, executing, leadership	Facilitators	<ul style="list-style-type: none"> <li>Improved visit structure</li> </ul>	<ul style="list-style-type: none"> <li>"CGM allows us to have a patient-centered exchange in reviewing the blood glucose and using shared decision making to determine next steps"</li> <li>"I have great support for getting prior authorizations for CGM but this process is still burdensome"</li> <li>"Developing a standardized process agreed upon by the entire practices"</li> <li>"EHR integration and reimbursement issues are solvable but our academic medical center gives little priority towards improved workflow"</li> </ul>
	Barriers	<ul style="list-style-type: none"> <li>Unclear delineation of device support roles by clinical staff vs device representatives</li> <li>Poor communication around proprietary device software updates, resulting in data access challenges</li> <li>Variation among providers within a clinic</li> <li>Lack of prioritization by health system leadership</li> </ul>	<ul style="list-style-type: none"> <li>"CGM allows us to have a patient-centered exchange in reviewing the blood glucose and using shared decision making to determine next steps"</li> <li>"I have great support for getting prior authorizations for CGM but this process is still burdensome"</li> <li>"Developing a standardized process agreed upon by the entire practices"</li> <li>"EHR integration and reimbursement issues are solvable but our academic medical center gives little priority towards improved workflow"</li> </ul>

Abbreviations: BG, blood glucose; CGM, continuous glucose monitoring; CFR, Consolidated Framework for Implementation Research; DME, durable medical equipment; EHR, electronic health record.

settings, improvements in data access are needed. Clearly defined workflows within a clinical practice setting, including designating a “diabetes technology champion,” and close collaboration with information technology support were identified as strategies to improve and maintain data access.<sup>37</sup> Recently, some diabetes practices have successfully collaborated with device manufacturers to directly integrate CGM data into the electronic health record,<sup>38–40</sup> a feature reported by only 14% of our respondents at the time of our survey.

Effective interpretation of CGM data requires time and improves with experience. We found that clinicians who saw a higher volume of patients using CGM reported higher perceived proficiency related to CGM. As CGM prescribing extends beyond diabetes specialists and into primary care settings, standardized training on CGM interpretation may support primary care providers for whom CGM-related education has been limited.<sup>41</sup> Existing education on standardized CGM data interpretation developed by national organizations including the American Diabetes Association and the American Association of Clinical Endocrinology could be leveraged. CGM data interpretation is time-intensive, and the majority of respondents reported inadequate time for data review, which is likely to be another barrier to widespread prescribing by primary care providers. Although reimbursement for CGM data interpretation was widely reported, reimbursement alone has not allowed diabetes clinicians to spend sufficient time on CGM-related activities. In the future, advanced decision support driven by machine learning may increasingly empower endocrinologists and primary care providers to efficiently interpret CGM data into actionable insights for patients.<sup>42,43</sup>

The greater clinical uptake of CGM has been accompanied by an increased recognition of disparities in use of diabetes technology. Recent studies have queried the combined role of provider implicit bias and systemic barriers in contributing to inequities in diabetes care and device use among patients with T1D.<sup>11,44–47</sup> In our study, while clinicians reported higher rates of CGM use in their patients than prior studies, they also highlighted factors beyond provider opinion that negatively influence CGM prescription, including high cost, insurance coverage, and burdensome documentation requirements. Addressing these external factors will require a multifaceted approach by policy makers, health systems, and manufacturers to ensure an equitable prescribing environment to increase CGM uptake in all eligible people with diabetes.<sup>48–50</sup>

We recognize several limitations of our study, including the cross-sectional nature and the dependence on self-reported data. Our study population was heavily skewed toward diabetes specialists at urban academic centers, so may not reflect practices of diabetes specialists and non-specialists in other settings. Perhaps most importantly, we focused only on those providers who *do* care for patients using CGM. We intentionally chose to focus on providers who use CGM to characterize current practices and challenges that will influence wider CGM uptake. However, the perspectives of diabetes providers who do not care for

patients using CGM, including primary care providers, are critical to understand as they provide care to a substantial portion of people with diabetes.<sup>51</sup> We found higher CGM use reported than prior T1D Exchange data,<sup>8</sup> which may reflect overestimation in self-report, but also likely reflects trends over time toward increasing CGM use. Future studies should further investigate CGM use in varying care delivery modalities, and deeper evaluation of these practices in non-academic and non-urban settings, as well as a focus on providers who do not regularly use CGM.

## Conclusions

Clinicians involved in diabetes care play an important role in promoting and supporting CGM use in their patients. Our results show that diabetes specialists strongly support CGM use and value CGM-generated data in routine diabetes care. Major barriers to CGM use include cost and challenges with insurance coverage. Related to CGM data review, improvements in clinical infrastructure, data access, EHR integration, and sufficient clinician time are required to support providers in caring for a growing population of people with diabetes using CGM. These implications are increasingly relevant as CGM use increases, including in nonacademic centers and in people with T2D.

## Abbreviations

CFIR, Consolidated Framework for Implementation Research; CGM, continuous glucose monitoring; DME, durable medical equipment; EHR, electronic health record; NIH, National Institutes of Health; PWD, people with diabetes; T1D, type 1 diabetes; T2D, type 2 diabetes.




## Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: T.K. has received consulting fees from Lilly. J.W. has received research support from Dexcom, Inc. and Tandem Diabetes; is a medical advisor; and co-founder of Tidepool (for which she receives no compensation). A.N. has received research support from Cisco Systems, Inc.; has received consulting fees from Lilly, Nokia Growth Partners, and Grand Rounds; serves as advisor to Steady Health (received stock options); has received speaking honoraria from Academy Health and Symposia Medicus; has written for WebMD (receives compensation); and is a medical advisor and co-founder of Tidepool (for which he receives no compensation).

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## ORCID iDs

Tejaswi Kompala  <https://orcid.org/0000-0002-4492-5035>  
Jenise Wong  <https://orcid.org/0000-0003-0573-6650>  
Aaron Neinstein  <https://orcid.org/0000-0002-9774-7180>



## References

1. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. *Ann Intern Med.* 2017;167(6):365-374. doi:10.7326/M16-2855
2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Ther Res Treat Educ Diabetes Relat Disord.* 2017;8(1):55-73. doi:10.1007/s13300-016-0223-6.
3. Park C, Le QA. The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis. *Diabetes Technol Ther.* 2018;20(9):613-621. doi:10.1089/dia.2018.0177.
4. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care.* 2019;dc190028. doi:10.2337/dci19-0028.
5. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *JAMA.* 2017;317:371-378. <https://jamanetwork.com/journals/jama/fullarticle/2598770>. Accessed March 29, 2021.
6. American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2020. *Diabetes Care.* 2020;43(suppl 1):S77-S88. doi:10.2337/dc20-S007.
7. Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology guideline resources. <https://www.endocrine.org/clinical-practice-guidelines/diabetes-technology>. Accessed March 29, 2021.
8. Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. *Diabetes Technol Ther.* 2019;21(2):66-72. doi:10.1089/dia.2018.0384.
9. Tanenbaum ML, Adams RN, Hanes SJ, et al. Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. *J Diabetes Sci Technol.* 2017;11(3):484-492. doi:10.1177/1932296816688010.
10. Bergloff A, Stratton E, Briggs Early K. A cross-sectional pilot survey of rural clinic attitudes and proficiency with insulin pumps and continuous glucose monitoring devices. *Diabetes Technol Ther.* 2019;21:665-670. doi:10.1089/dia.2019.0161.
11. Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. *Diabetes Technol Ther.* 2021;23:306-313. doi:10.1089/dia.2020.0338.
12. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci IS.* 2009;4:50. doi:10.1186/1748-5908-4-50.
13. Wong JC, Neinstein AB, Spindler M, Adi S. A minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device data. *Diabetes Technol Ther.* 2015;17(8):555-562. doi:10.1089/dia.2014.0413.
14. American Diabetes Association. 6. Glycemic Targets: standards of medical care in diabetes—2021. *Diabetes Care.* 2021;44(suppl 1):S73-S84. doi:10.2337/dc21-S006.
15. Original Research Reports & Market Research Studies from Qualtrics. <https://www.qualtrics.com/research-center/>. Accessed July 3, 2021.
16. National Institutes of Health. Competencies Proficiency Scale. <https://hr.nih.gov/working-nih/competencies/competencies-proficiency-scale>. Published May 17, 2017. Accessed March 29, 2021.
17. Sarkies M, Long JC, Pomare C, et al. Avoiding unnecessary hospitalisation for patients with chronic conditions: a systematic review of implementation determinants for hospital avoidance programmes. *Implement Sci.* 2020;15(1):91. doi:10.1186/s13012-020-01049-0.
18. Holmes JA, Logan P, Morris R, Radford K. Factors affecting the delivery of complex rehabilitation interventions in research with neurologically impaired adults: a systematic review. *Syst Rev.* 2020;9(1):268. doi:10.1186/s13643-020-01508-1.
19. Lee PA, Greenfield G, Pappas Y. The impact of telehealth remote patient monitoring on glycemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials. *BMC Health Serv Res.* 2018;18(1):495. doi:10.1186/s12913-018-3274-8.
20. FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. *BMC Med Ethics.* 2017;18:19 <https://bmcmethics-biomedcentral-com.ucsf.idm.oclc.org/articles/10.1186/s12910-017-0179-8?report=reader>. Accessed March 29, 2021.
21. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. *Am J Public Health.* 2015;105(12):e60-e76. doi:10.2105/AJPH.2015.302903.
22. Willi SM, Miller KM, DiMeglio LA, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. *Pediatrics.* 2015;135(3):424-434. doi:10.1542/peds.2014-1774.
23. Puckett C, Wong JC, Daley TC, Cossen K. How organizations shape medical technology allocation: Insulin pumps and pediatric patients with type 1 diabetes. *Soc Sci Med.* 2020;249:112825. doi:10.1016/j.socscimed.2020.112825.
24. Powell RE, Zaccardi F, Beebe C, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab.* 2021;23:2137-2154. doi:10.1111/dom.14455.
25. Döğer E, Bozbulut R, Soysal Acar AŞ, et al. Effect of telehealth system on glycemic control in children and adolescents with type 1 diabetes. *J Clin Res Pediatr Endocrinol.* 2019;11(1):70-75. doi:10.4274/jcrpe.galenos.2018.2018.0017.
26. Pierce JS, Gurnurkar S, Vyas N, Carakushansky M, Owens L, Patton SR. Feasibility of implementing a pediatric diabetes clinic via telehealth. *Diabetes Spectr.* 2021;34:90-197. doi:10.2337/ds20-0060
27. Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities. *Diabetes Technol Ther.* 2020;22(6):431-439. doi:10.1089/dia.2020.0161.
28. Fung A, Irvine M, Ayub A, Ziabakhsh S, Amed S, Hursh BE. Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic. *J Clin Transl Endocrinol.* 2020;22:100238. doi:10.1016/j.jcte.2020.100238.
29. Mehrotra A, Chernew ME, Linetsky D, Hatch H, Cutler D, Schneider E. The Impact of the COVID-19 Pandemic on

- Outpatient Visits: Changing Patterns of Care in the Newest COVID-19 Hot Spots. doi:10.26099/yaqe-q550.
30. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D, Schneider E. The Impact of COVID-19 on Outpatient Visits in 2020: Visits Remained Stable, Despite a Late Surge in Cases. <https://www.commonwealthfund.org/publications/2021/feb/impact-covid-19-outpatient-visits-2020-visits-stable-despite-late-surge>. Accessed March 29, 2021.
  31. Ramchandani N. Virtual coaching to enhance diabetes care. *Diabetes Technol Ther*. 2019;21(suppl 2):S248-S251. doi:10.1089/dia.2019.0016.
  32. Crossen S, Raymond J, Neinstein A. Top 10 tips for successfully implementing a diabetes telehealth program. *Diabetes Technol Ther*. 2020;22:920-928. doi:10.1089/dia.2020.0042.
  33. Levine BJ, Close KL, Gabbay RA. Reviewing U.S. connected diabetes care: the newest member of the team. *Diabetes Technol Ther*. 2019;22(1):1-9. doi:10.1089/dia.2019.0273.
  34. Majithia AR, Kusiak CM, Armento Lee A, et al. Glycemic outcomes in adults with type 2 diabetes participating in a continuous glucose monitor-driven virtual diabetes clinic: prospective trial. *J Med Internet Res*. 2020;22(8):e21778. doi:10.2196/21778.
  35. Isaacson B, Kaufusi S, Sorensen J, et al. Demonstrating the clinical impact of continuous glucose monitoring within an integrated healthcare delivery system. *J Diabetes Sci Technol*. 2020;16:383-389. doi:10.1177/1932296820955228.
  36. Oikonomidi T, Ravaud P, Cosson E, Montori V, Tran VT. Evaluation of patient willingness to adopt remote digital monitoring for diabetes management. *JAMA Netw Open*. 2021;4(1):e2033115. doi:10.1001/jamanetworkopen.2020.33115.
  37. Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. *JAMA*. 2021;325(22):2262. doi:10.1001/jama.2021.7444.
  38. Espinoza J, Shah P, Raymond J. Integrating continuous glucose monitor data directly into the electronic health record: proof of concept. *Diabetes Technol Ther*. 2020;22(8):570-576. doi:10.1089/dia.2019.0377.
  39. Prahalad P, Zaharieva DP, Addala A, et al. Improving clinical outcomes in newly diagnosed pediatric type 1 diabetes: team-work, targets, technology, and tight control—the 4T study. *Front Endocrinol*. 2020;11. doi:10.3389/fendo.2020.00360.
  40. Adding CGM data to EHR could boost use in primary care diabetes management. <https://www.healio.com/news/endocrinology/20210706/adding-cgm-data-to-ehr-could-boost-use-in-primary-care-diabetes-management>. Accessed August 15, 2021.
  41. Morales J, Kuritzky L, Lavernia F, Santiago M. Are residents receiving the training needed within their residency programs to optimally manage patients with diabetes? *Postgrad Med*. 2021;133(4):388-394. doi:10.1080/00325481.2020.1857603.
  42. Nimri R, Dassau E, Segall T, et al. Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: variations among countries and physicians. *Diabetes Obes Metab*. 2018;20(10):2458-2466. doi:10.1111/dom.13408.
  43. Nimri R, Battelino T, Laffel LM, et al. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. *Nat Med*. 2020;26(9):1380-1384. doi:10.1038/s41591-020-1045-7.
  44. Fantasia KL, Wirunsawanya K, Lee C, Rizo I. Racial disparities in diabetes technology use and outcomes in type 1 diabetes in a safety-net hospital. *J Diabetes Sci Technol*. 2021;15:1010-1017. doi:10.1177/1932296821995810.
  45. Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. *Diabetes Care*. 2021;44(1):133-140. doi:10.2337/dc20-0257.
  46. Walker AF, Hood KK, Gurka MJ, et al. Barriers to technology use and endocrinology care for underserved communities with type 1 diabetes. *Diabetes Care*. 2021;44:1480-1490. doi:10.2337/dc20-2753.
  47. Agarwal S, Kanapka LG, Raymond JK, et al. Racial-ethnic inequity in young adults with type 1 diabetes. *J Clin Endocrinol Metab*. 2020;105(8). doi:10.1210/clinem/dgaa236.
  48. Peek ME, Thomas CC. Broadening access to continuous glucose monitoring for patients with type 2 diabetes. *JAMA*. 2021;325(22):2255. doi:10.1001/jama.2021.6208.
  49. Anderson JE, Gavin JR, Kruger DF. Current eligibility requirements for CGM coverage are harmful, costly, and unjustified. *Diabetes Technol Ther*. 2020;22(3):169-173. doi:10.1089/dia.2019.0303.
  50. Galindo RJ, Parkin CG, Aleppo G, et al. What's wrong with this picture? a critical review of current centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring. *Diabetes Technol Ther*. 2021;23:652-660. doi:10.1089/dia.2021.0107.
  51. Lal RA, Cuttriss N, Haller MJ, et al. Primary care providers in California and Florida Report low confidence in providing type 1 diabetes care. *Clin Diabetes*. 2020;38(2):159-165. doi:10.2337/cd19-0060.